French pharmaceutical company Sanofi has entered into a EUR 130 million strategic alliance with fellow French company Oncodesign to find new kinase inhibitors for a variety of indications.
As part of the four year contract, Oncodesign will apply its proprietary Nanocyclix to provide a medicinal chemistry platform for the discovery and development of inhibitors against unknown kinase targets.
[ilink url=“http://www.pmlive.com/pharma_news/sanofi_taps_oncodesign_for_kinase_inhibitor_platform_425632″] Link zur Quelle (pmlive.com)[/ilink]